Lakewood-Amedex Biotherapeutics announced positive progress for Nu-3, a topical antimicrobial gel targeting mildly infected diabetic foot ulcers (iDFU). The company has completed key formulation and manufacturing steps under cGMP guidelines, ensuring drug stability and effectiveness for clinical use. Nu-3 belongs to the Bisphosphocin® class, which rapidly kills bacteria including resistant strains like MRSA and VRE, potentially reducing antimicrobial resistance risks. The next step is a planned Phase 2 clinical trial to evaluate safety, dosage, and treatment efficacy for iDFU patients.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Experian PLC started its 2027 financial year with a 10% revenue increase in the first quarter, driven by strong demand in North America and Latin America. Organic growth was 7%, with North America growing 7% despite a 2% drop in consumer services due...
Gooch & Housego, a UK-listed photonics company specializing in precision optics for aerospace and defence, has agreed to a £345.6 million takeover by US private equity firm Arlington Capital Partners. The offer values the company at a 41.3% premium t...
Aave DAO has proposed an innovative mobile app that integrates fiat currency deposits, self-custody, and decentralized finance (DeFi) lending in one platform. This app allows users to convert fiat to stablecoins and earn yields without needing extern...
Analysts expect Netflix to report $12.6 billion in revenue for Q2 and $51.3 billion for the full year 2026. The operating margin forecast has been revised down from 33% to 32% due to anticipated higher expenses, with an expected operating profit of $...
